Search
rizatriptan (Maxalt, Maxalt-MLT)
Tradenames: Maxalt, Maxalt-MLT. Rizatriptan benzoate.
Indications: migraine headache
Contraindications:
-> concurrent use of MAO inhibitor (use 2 week washout)
Dosage:
1) 5-10 mg PO, may repeat in 2 hours
2) maximum: 30 mg QD
Tabs: 5, 10 mg
Sublingual: Maxalt MLT
Pharmacokinetics:
1) onset of action faster than other triptans
2) metabolized via monoamine oxidase
Adverse effects:
1) most common (1-10%)
- paresthesia, chest pressure, neck, throat or jaw pain, dry mouth, nausea, dizziness, somnolence, asthenia, fatigue, tachycardia, hypertension, diarrhea, palpitations, constipation, flatulence, tongue edema, decreased mental accuity, euphoria, tremor, dyspnea, flushing, hot flashes
2) uncommon (< 1%)
- myalgia, arthralgia, muscle spasm, nasal congestion, epistaxis, blurred vision, tinnitus, dry eyes, pruritus, rash, urticaria, polyuria
3) rare
- coronary artery vasospasm
- transient myocardial ischemia
- myocardial infarction
- ventricular tachycardia
- ventricular fibrillation
4) overdose
- syncope
- bradycardia
- vomiting
- 3rd degree AV block
5) frequent use may exacerbate migraines [3]
Drug interactions:
-> concurrent use of propranolol may increase levels of rizatriptan: reduce dose of rizatriptan [4]
Interactions
drug interactions
drug adverse effects of triptan(s)
General
amine
indole
serotonin agonist (5-HT receptor agonist, triptan)
Properties
MISC-INFO: elimination route LIVER
onset-of-action 1-1.5 HOURS {ORAL}
1/2life 2-3 HOURS
protein-binding 14%
Database Correlations
PUBCHEM correlations
References
- Merck & Company
- Kaiser Permanente Northern California Regional Drug
Formulary (update 3/2000)
- Prescriber's Letter 9(2):8 2002
- Prescriber's Letter 10(3):14-15 2003
Substructures
triazole; pyrrodiazole